InvestorsHub Logo
Followers 234
Posts 26887
Boards Moderated 0
Alias Born 01/12/2013

Re: ralphey post# 116662

Monday, 10/23/2017 7:12:06 PM

Monday, October 23, 2017 7:12:06 PM

Post# of 427300
Ralpher-JZ valued the stock at "nothing less than $30".... and that was prior to Marine approval without disparaging "ANCHOR study free" Marine label; this action directly place Vascepa at a huge disadvantage compared to Lovaza. Also at this time the FDA withheld NCE out of indecision...than delayed it for spite.

If R-I is successful and Amarin can uphold patents via ITC action the stock is worth greater than $150 per share.

BB

Mr. McGee, don't make me angry. You wouldn't like me when I'm angry---David Banner

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News